22:11 , Nov 7, 2018 |  BC Innovations  |  Translation in Brief

M is for Chemoproteomic Momentum

An October...
01:35 , Aug 11, 2017 |  BC Innovations  |  Tools & Techniques

K follows C in chemoproteomics

A year after publishing a map of druggable cysteines in the proteome, Ben Cravatt’s lab at Scripps has reported its chemoproteomics tools can also profile lysines. By identifying reactive lysines in dozens of proteins for...
23:54 , Feb 24, 2017 |  BC Extra  |  Company News

Management Tracks

Celgene Corp. (NASDAQ:CELG) said President and COO Jacqualyn Fouse will retire on June 30. Scott Smith will succeed Fouse effective April 1. He is president of global inflammation and immunology. Terrie Curran will be promoted...
07:00 , May 24, 2012 |  BC Innovations  |  Targets & Mechanisms

Getting selective for gamma

Cellzome AG and Exelixis Inc. have independently designed the first highly selective inhibitors of the g-isoform of phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome by GlaxoSmithKline...
07:00 , Oct 2, 2008 |  BC Innovations  |  Cover Story

Truly Boronic

Researchers at Tufts University have shown that peptide boronic acid inhibitors of dipeptidyl peptidase-4 could provide effective, low-toxicity treatments for diabetes. 1 The findings challenge the long-held assumption that boronic acids are too toxic for...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Clinical News

KRP-104: Phase Ib data

Top-line data from an open-label, U.S. Phase Ib trial in 28 patients with Type II diabetes showed that KRP-104 was non-inferior to an undisclosed competitor in lowering glucose. KRP-104 is being developed by Kyorin’s ActivX...
07:00 , Aug 25, 2008 |  BC Week In Review  |  Clinical News

KRP-104: Phase IIa data

Top-line data from a double-blind, placebo-controlled, U.S. and Indian Phase IIa trial in 220 patients with Type II diabetes inadequately controlled on metformin alone, showed that KRP-104 administered twice-daily at 60 mg or once-daily at...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Company News

ActivX sales and marketing update

ActivX launched its KiNativ assay for profiling kinases and discovering kinase inhibitors. ActivX Biosciences Inc. , La Jolla, Calif.   Business: Computational chemistry/biology  ...
08:00 , Mar 5, 2007 |  BC Week In Review  |  Company News

Ligand board of directors update

Ligand Pharmaceuticals Inc. (LGND), San Diego, Calif.   Business: Cancer, Inflammation   Appointed: John Kozarich, a director of LGND and president and chairman of Kyorin Pharmaceuticals Co. Ltd.'s ActivX Biosciences Inc. subsidiary, as chairman; he...
08:00 , Mar 20, 2006 |  BC Week In Review  |  Company News

Kyorin, Pfizer deal

PFE and Kyorin's ActivX Biosciences Inc. subsidiary (La Jolla, Calif.) renewed their 2005 deal under which ActivX is providing chemistry and protein analysis services for certain PFE discovery programs (see BioCentury, Feb. 14, 2005). ActivX...